Overview

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2012-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
UCB Pharma
Treatments:
Inotuzumab Ozogamicin
Rituximab